ClinicalTrials.gg
CompletedNCT01430442Updated Feb 28, 2023Results posted

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

A Phase 2 interventional study of Rimegepant and Placebo in Migraine and Acute Treatment of Migraine, sponsored by Pfizer. Completed at 41 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-02-28.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,026
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Enrollment
9th of 32
1,026 · median 618
Started
2011
with 1 other
Phase 2
4 of 32
2 open now
Registered
1st of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 9th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 2, and was the 1st registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain") at 2 hours post dose using a four point numeric rating scale (no pain, mild pain, moderate pain, severe pain) while identifying an optimal dose to support the Phase 3 clinical trials.

Read the detailed description

Intervention Model: Parallel Versus Comparator + Placebo

03

Conditions studied

  • Migraine
  • Acute Treatment of Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patient with at least 1-year history of migraines (with or without aura) including the following:

    • Migraine attacks more than 1 year with age of onset prior to 50 years of age
    • Migraine attacks, on average, last about 4 - 72 hours if untreated
    • No more than 8 attacks of moderate to severe intensity per month within last 3 months
    • Patient must be able to distinguish migraine attacks from tension/cluster attacks and must have consistent migraine headaches of at least 2 migraine headaches attacks of moderate to severe intensity in each of the last 3 months
    • Less than 15 days of headache (migraine or non-migraine) per month in each of 3 months prior to screening
  • Male and female ≥ 18 years and ≤ age 65
  • No abnormality identified on the medical or laboratory evaluation

Key Exclusion Criteria:

  • Patient has a history of basilar migraine or hemiplegic migraine
  • Patient does not receive migraine relief from triptan migraine treatment
  • Medications that may alter the pH of the stomach (acid reducing agents), such as H-2 antagonists, Proton Pump inhibitors (PPI), antacids
  • History of ergotamine or triptan intake greater than/equal 10 days per month on a regular basis for greater than 3 months
  • History of non-narcotic analgesic intake on greater then/equal 15 days per month for greater than/equal 3 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,026 participants (actual)

Study arms

  • Experimental
    Treatment A: Rimegepant, 10 mg

    Participants received a single dose (one capsule) of rimegepant 10 milligram (mg) orally and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.

    Drug: Rimegepant · Drug: Placebo

  • Experimental
    Treatment B: Rimegepant, 25 mg

    Participants received a single dose (one capsule) of rimegepant 25 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.

    Drug: Rimegepant · Drug: Placebo

  • Experimental
    Treatment C: Rimegepant, 75 mg

    Participants received a single dose (one capsule) of rimegepant 75 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.

    Drug: Rimegepant · Drug: Placebo

  • Experimental
    Treatment D: Rimegepant, 150 mg

    Participants received a single dose (one capsule) of rimegepant 150 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.

    Drug: Rimegepant · Drug: Placebo

  • Experimental
    Treatment E: Rimegepant, 300 mg

    Participants received a single dose (two 150 mg capsules) of rimegepant 300 mg orally; and two rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.

    Drug: Rimegepant · Drug: Placebo

  • Experimental
    Treatment F: Rimegepant, 600 mg

    Participants received a single dose (four capsules of 150 mg each) of rimegepant 600 mg orally; anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.

    Drug: Rimegepant · Drug: Placebo

  • Placebo comparator
    Treatment P: Rimegepant Placebo-Matching Capsules

    Participants received a single dose (4 capsules) of rimegepant placebo-matching capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.

    Drug: Placebo

  • Active comparator
    Treatment G: Sumatriptan 100 mg

    Participants received a single dose (one capsule) of rimegepant-matching sumatriptan 100 mg orally and three rimegepant matching placebo capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.

    Drug: Placebo · Drug: Sumatriptan

Interventions

  • Rimegepant capsules

  • DrugPlacebo

    Rimegepant placebo-matching capsules

  • Rimegepant matching sumatriptan and Rimegepant matching placebo capsules

    Also known as: Imitrex®

06

What researchers measure

Primary outcomes

  1. Number of Pain Free Participants (Pain Freedom) at 2 Hours Post-dose

    Pain freedom was defined as participants reporting a value of "none" on the four-point numeric rating scale (none=0, mild =1, moderate =2, severe =3) from baseline. Participants with baseline moderate pain or severe pain were included in the analysis.

    Time frame: Baseline, 2 hours post-dose

Secondary outcomes

  1. Number of Participants With Total Migraine Freedom at 2 Hours Post Dose

    Total migraine freedom is defined as complete absence of migraine symptoms. A participant was positive for total migraine freedom at a particular time point if he/she reports the absence of: pain, nausea, photophobia, and phonophobia. This corresponds to reporting "none" on each of the four-point numeric rating scale (none =0, mild =1, moderate =2, severe =3) from baseline associated with these symptoms. Participants with baseline moderate pain or severe pain were included in the analysis.

    Time frame: Baseline, 2 hours post dose

  2. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuation Due to Adverse Events

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition, unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or suspected transmission of an infectious agent, or encompassed any other clinically significant event that could jeopardize the subject or require medical or surgical intervention to prevent one of the aforementioned outcomes.

    Time frame: AEs: from first dose to end of treatment visit (up to 7 weeks); SAE: from signing of informed consent to 30 days after the last dose (up to 11 weeks).

  3. Number of Participants Achieving Sustained Pain Freedom From 2 to 24 Hours Post Dose

    Participants were considered to have sustained pain freedom if all of their reported pain readings in the interval are "none" on the four point numeric rating scale (no pain=0, mild pain=1, moderate pain=2, severe pain=3). The intervals are inclusive of the endpoints. Sustained pain freedom was analyzed with a Cochran Mantel Haenszel (CMH) test for general association that compares the ED90 to placebo, and controls for baseline pain severity.

    Time frame: 2 hours to 24 hours post dose

  4. Number of Participants Achieving Sustained Pain Freedom From 2 to 48 Hours Post Dose

    Participants were considered to have sustained pain freedom if all of their reported pain readings in the interval are "none" on the four point numeric rating scale (no pain=0, mild pain=1, moderate pain=2, severe pain=3). The intervals are inclusive of the endpoints. Sustained pain freedom was analyzed with a CMH test for general association that compares the ED90 to placebo, and controls for baseline pain severity.

    Time frame: 2 hours to 48 hours post dose

07

Results

Posted Sep 3, 2020

Participant flow

The study was conducted at 41 centers in the United States. A total of 1026 participants were enrolled in the study, and 885 of these were randomized to treatment. Of the 141 participants who were not randomized, the main reason for non-randomization was participants no longer met inclusion criteria.

Participant flow — Overall Study
MilestoneTreatment A: Rimegepant, 10 mgTreatment B: Rimegepant, 25 mgTreatment C: Rimegepant, 75 mgTreatment D: Rimegepant, 150 mgTreatment E: Rimegepant, 300 mgTreatment F: Rimegepant, 600 mgTreatment P: Rimegepant Placebo-Matching CapsulesTreatment G: Sumatriptan 100 mg
Started8568919012192229109
Completed7262868611284210100
Not completed1365498199
Withdrew: Subject withdrew consent30102152
Withdrew: Lost to follow-up20122151
Withdrew: Pregnancy10000100
Withdrew: Patient no longer meets study criteria76325596

Outcome measures

PrimaryNumber of Pain Free Participants (Pain Freedom) at 2 Hours Post-dose

Pain freedom was defined as participants reporting a value of "none" on the four-point numeric rating scale (none=0, mild =1, moderate =2, severe =3) from baseline. Participants with baseline moderate pain or severe pain were included in the analysis.

Time frame:
Baseline, 2 hours post-dose
Reported as:
Count of participants · Participants
Number of Pain Free Participants (Pain Freedom) at 2 Hours Post-dose
ParticipantsTreatment A: Rimegepant, 10 mgTreatment B: Rimegepant, 25 mgTreatment C: Rimegepant, 75 mgTreatment D: Rimegepant, 150 mgTreatment E: Rimegepant, 300 mgTreatment F: Rimegepant, 600 mgTreatment P: Rimegepant Placebo-Matching CapsulesTreatment G: Sumatriptan 100 mg
Number of Pain Free Participants (Pain Freedom) at 2 Hours Post-dose1412272833203135
SecondaryNumber of Participants With Total Migraine Freedom at 2 Hours Post Dose

Total migraine freedom is defined as complete absence of migraine symptoms. A participant was positive for total migraine freedom at a particular time point if he/she reports the absence of: pain, nausea, photophobia, and phonophobia. This corresponds to reporting "none" on each of the four-point numeric rating scale (none =0, mild =1, moderate =2, severe =3) from baseline associated with these symptoms. Participants with baseline moderate pain or severe pain were included in the analysis.

Time frame:
Baseline, 2 hours post dose
Reported as:
Count of participants · Participants
Number of Participants With Total Migraine Freedom at 2 Hours Post Dose
ParticipantsTreatment A: Rimegepant, 10 mgTreatment B: Rimegepant, 25 mgTreatment C: Rimegepant, 75 mgTreatment D: Rimegepant, 150 mgTreatment E: Rimegepant, 300 mgTreatment F: Rimegepant, 600 mgTreatment P: Rimegepant Placebo-Matching CapsulesTreatment G: Sumatriptan 100 mg
Number of Participants With Total Migraine Freedom at 2 Hours Post Dose1311242226162432
SecondaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuation Due to Adverse Events

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition, unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or suspected transmission of an infectious agent, or encompassed any other clinically significant event that could jeopardize the subject or require medical or surgical intervention to prevent one of the aforementioned outcomes.

Time frame:
AEs: from first dose to end of treatment visit (up to 7 weeks); SAE: from signing of informed consent to 30 days after the last dose (up to 11 weeks).
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuation Due to Adverse Events
ParticipantsTreatment A: Rimegepant, 10 mgTreatment B: Rimegepant, 25 mgTreatment C: Rimegepant, 75 mgTreatment D: Rimegepant, 150 mgTreatment E: Rimegepant, 300 mgTreatment F: Rimegepant, 600 mgTreatment P: Rimegepant Placebo-Matching CapsulesTreatment G: Sumatriptan 100 mg
AEs1510181218142917
SAEs00030000
Participants discontinued due to AEs00000000
SecondaryNumber of Participants Achieving Sustained Pain Freedom From 2 to 24 Hours Post Dose

Participants were considered to have sustained pain freedom if all of their reported pain readings in the interval are "none" on the four point numeric rating scale (no pain=0, mild pain=1, moderate pain=2, severe pain=3). The intervals are inclusive of the endpoints. Sustained pain freedom was analyzed with a Cochran Mantel Haenszel (CMH) test for general association that compares the ED90 to placebo, and controls for baseline pain severity.

Time frame:
2 hours to 24 hours post dose
Reported as:
Count of participants · Participants
Number of Participants Achieving Sustained Pain Freedom From 2 to 24 Hours Post Dose
ParticipantsTreatment A: Rimegepant, 10 mgTreatment B: Rimegepant, 25 mgTreatment C: Rimegepant, 75 mgTreatment D: Rimegepant, 150 mgTreatment E: Rimegepant, 300 mgTreatment F: Rimegepant, 600 mgTreatment P: Rimegepant Placebo-Matching CapsulesTreatment G: Sumatriptan 100 mg
Number of Participants Achieving Sustained Pain Freedom From 2 to 24 Hours Post Dose910242429171526
SecondaryNumber of Participants Achieving Sustained Pain Freedom From 2 to 48 Hours Post Dose

Participants were considered to have sustained pain freedom if all of their reported pain readings in the interval are "none" on the four point numeric rating scale (no pain=0, mild pain=1, moderate pain=2, severe pain=3). The intervals are inclusive of the endpoints. Sustained pain freedom was analyzed with a CMH test for general association that compares the ED90 to placebo, and controls for baseline pain severity.

Time frame:
2 hours to 48 hours post dose
Reported as:
Count of participants · Participants
Number of Participants Achieving Sustained Pain Freedom From 2 to 48 Hours Post Dose
ParticipantsTreatment A: Rimegepant, 10 mgTreatment B: Rimegepant, 25 mgTreatment C: Rimegepant, 75 mgTreatment D: Rimegepant, 150 mgTreatment E: Rimegepant, 300 mgTreatment F: Rimegepant, 600 mgTreatment P: Rimegepant Placebo-Matching CapsulesTreatment G: Sumatriptan 100 mg
Number of Participants Achieving Sustained Pain Freedom From 2 to 48 Hours Post Dose89242429171526

Adverse events

Collected over AEs: from first dose to end of treatment visit (up to 52 days); SAE: from signing of informed consent to 30 days after the last dose (up to 80 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: Rimegepant, 10 mg0/85 (0%)0/72 (0%)4/72 (5.6%)
Treatment B: Rimegepant, 25 mg0/68 (0%)0/62 (0%)0/62 (0%)
Treatment C: Rimegepant, 75 mg0/91 (0%)0/86 (0%)3/86 (3.5%)
Treatment D: Rimegepant, 150 mg0/90 (0%)3/86 (3.5%)3/86 (3.5%)
Treatment E: Rimegepant, 300 mg0/121 (0%)0/112 (0%)6/112 (5.4%)
Treatment F: Rimegepant, 600 mg0/92 (0%)0/84 (0%)7/84 (8.3%)
Treatment P: Rimegepant Placebo-Matching Capsules0/229 (0%)0/209 (0%)5/209 (2.4%)
Treatment G: Sumatriptan 100 mg0/109 (0%)0/100 (0%)2/100 (2%)
Most frequent serious events
Most frequent serious events
EventTreatment A: Rimegepant, 10 mgTreatment B: Rimegepant, 25 mgTreatment C: Rimegepant, 75 mgTreatment D: Rimegepant, 150 mgTreatment E: Rimegepant, 300 mgTreatment F: Rimegepant, 600 mgTreatment P: Rimegepant Placebo-Matching CapsulesTreatment G: Sumatriptan 100 mg
PNEUMONIAInfections and infestations0/720/620/861/860/1120/840/2090/100
POST LUMBAR PUNCTURE SYNDROMEInjury, poisoning and procedural complications0/720/620/861/860/1120/840/2090/100
STRESS CARDIOMYOPATHYCardiac disorders0/720/620/861/860/1120/840/2090/100
Most frequent other events
Most frequent other events
EventTreatment A: Rimegepant, 10 mgTreatment B: Rimegepant, 25 mgTreatment C: Rimegepant, 75 mgTreatment D: Rimegepant, 150 mgTreatment E: Rimegepant, 300 mgTreatment F: Rimegepant, 600 mgTreatment P: Rimegepant Placebo-Matching CapsulesTreatment G: Sumatriptan 100 mg
NAUSEAGastrointestinal disorders1/720/623/863/865/1127/845/2092/100
DIARRHOEAGastrointestinal disorders4/720/620/860/861/1120/840/2090/100

Baseline characteristics

The analysis was performed in randomized population defined as all participants who were randomized to double-blind treatment.

Age, Continuous
Age, Continuous(years)Treatment A: Rimegepant, 10 mgTreatment B: Rimegepant, 25 mgTreatment C: Rimegepant, 75 mgTreatment D: Rimegepant, 150 mgTreatment E: Rimegepant, 300 mgTreatment F: Rimegepant, 600 mgTreatment P: Rimegepant Placebo-Matching CapsulesTreatment G: Sumatriptan 100 mgTotal
Mean41.1 ± 10.3636.5 ± 11.9238.5 ± 11.8739.2 ± 11.2641.9 ± 11.4639.3 ± 13.0137.9 ± 11.3640.6 ± 10.4739.3 ± 11.52
Sex: Female, Male
Sex: Female, Male(Participants)Treatment A: Rimegepant, 10 mgTreatment B: Rimegepant, 25 mgTreatment C: Rimegepant, 75 mgTreatment D: Rimegepant, 150 mgTreatment E: Rimegepant, 300 mgTreatment F: Rimegepant, 600 mgTreatment P: Rimegepant Placebo-Matching CapsulesTreatment G: Sumatriptan 100 mgTotal
Female676181631017619691736
Male187102720163318149
08

Study locations

41 sites
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
  • Clinical Res. Advantage Inc/ Desert Clinical Research Llc
    Tempe, Arizona 85282, United States
  • University Of California, San Francisco
    San Francisco, California 94115, United States
  • California Medical Clinic For Headache
    Santa Monica, California 90404, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Radiant Research, Inc.
    Denver, Colorado 80239, United States
  • Miami Research Associates
    Miami, Florida 33143, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Compass Research, Llc
    Orlando, Florida 32806, United States
  • Broward Research Group
    Pembroke Pines, Florida 33026, United States
  • Comprehensive Clinical Development, Inc
    Saint Petersburg, Florida 33716, United States
  • Diamond Headache Clinic, Ltd.
    Chicago, Illinois 60642, United States
  • Milford Emergency Associates, Inc.
    Milford, Massachusetts 01757, United States
  • Medvadis Research Corporation
    Watertown, Massachusetts 02472-3930, United States
  • Michigan Head Pain And Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Clinical Research Institute, Inc.
    Minneapolis, Minnesota 55402, United States
  • The Center For Pharmaceutical Research. Pc
    Kansas City, Missouri 64114, United States
  • Mercy Health Research
    Saint Louis, Missouri 63141, United States
  • Clinvest/ A Division Of Banyan Group, Inc.
    Springfield, Missouri 65807, United States
  • Regional Clinical Research Inc.
    Endwell, New York 13760, United States
  • Central New York Clinical Research
    Manlius, New York 13104, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • Pharmquest
    Greensboro, North Carolina 27408, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Pmg Research Of Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • Community Research
    Cincinnati, Ohio 45227, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Clinical Research Of Philadelphia, Llc
    Philadelphia, Pennsylvania 19114, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Coastal Carolina Research Center, Inc.
    Mount Pleasant, South Carolina 29464, United States
  • Clinsearch, Llc
    Chattanooga, Tennessee 37421, United States
  • Premier Research Group Limited
    Austin, Texas 78705, United States
  • Futuresearch Trials Of Neurology
    Austin, Texas 78731, United States
  • R/D Clinical Research, Inc.
    Lake Jackson, Texas 77566, United States
  • J. Lewis Research, Inc
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc
    Salt Lake City, Utah 84121, United States
  • The Innovative Clinical Research Center
    Alexandria, Virginia 22304, United States
  • Tidewater Integrated Medical Research
    Virginia Beach, Virginia 23454, United States
  • Swedish Pain And Headache Center
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014 Feb;34(2):114-25. doi: 10.1177/0333102413500727. Epub 2013 Aug 21. PubMed 23965396 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2011 to primary completion in May 2012, 7 months.

Results were first posted in Sep 2020, 8 years 4 months after primary completion. A results delay was requested in Sep 2015.

Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 7 months is below that.

Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2011
First posted
Sep 8, 2011
StartActual
Oct 2011
Primary completionActual
May 2012
CompletionActual
May 2012
Results delay requested
Sep 23, 2015
Results first posted
Sep 3, 2020
Last update
Feb 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01430442
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 8, 2011
Start date
Oct 2011
Primary completion
May 2012
Completion
May 2012
Results posted
Sep 3, 2020
Last update
Feb 28, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion